logo-loader
viewSmith & Nephew PLC

Smith & Nephew increasingly confident underlying revenue growth to be in upper half of guidance

The FTSE 100-listed firm said Q1 revenue was US$1.202bn (2018: US$1.196bn), up 4.4% on an underlying basis, with reported growth of 0.5% after a -3.9% foreign exchange headwind

Knee replacements
The orthopaedic products manufacturer said all three of its global franchises saw an acceleration, delivering growth ahead of full-year 2018

Smith & Nephew PLC (LON:SN.) shares rose on Thursday as the medical devices group as it said it is increasingly confident its underlying revenue growth will be in the upper half of the guidance as in reported a rise in first-quarter revenue.

In a trading report for the first quarter ended 30 March 2019, the FTSE 100-listed firm said Q1 revenue was US$1.202bn (2018: US$1.196bn), up 4.4% on an underlying basis, with reported growth of 0.5% after a -3.9% foreign exchange headwind.

READ: Smith & Nephew paying around $660mln in cash to acquire US regenerative medicine firm Osiris Therapeutics

The orthopaedic products manufacturer said all three of its global franchises saw an acceleration, delivering growth ahead of full-year 2018 as it started to benefit from a new commercial model.

The firm highlighted mid-teens growth from Emerging Markets, led by a strong quarter in China.

It also noted rapid progress in its M&A strategy, securing additional growth drivers and building its technology base  following the recent acquisitions of US firms Ceterix Orthopaedics, Osiris Therapeutics, Leaf Patient Monitoring System, and Brainlab.

The group it is increasingly confident that underlying revenue growth will be in the upper half of its 2.5% to 3.5% guidance range, with expected trading profit margin unchanged in the range of 22.8% to 23.2%.

Good start to year

Namal Nawana, the firm’s chief executive officer, commented: "It's been a good start to 2019 across the whole of Smith & Nephew.”

He added: "All three global franchises delivered improved organic growth as we continued to improve execution; important confirmation that each has the potential to perform sustainably at or above their markets.

"At the same time, we've made well-judged acquisitions that bring in new technologies to strengthen leadership positions across the business, which we expect to further accelerate growth over time.”

The boss concluded: "While recognising that further work remains to achieve the full potential of our portfolio, we are encouraged with our progress towards sustainably delivering above-market growth."

In early morning trading, shares in Smith & Nephew topped the blue-chip leader board, up 2.9% at 1,517p.

Quick facts: Smith & Nephew PLC

Price: 49.48 USD

NYSE:SNN
Market: NYSE
Market Cap: $21.65 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks slow down but show no signs of giving up last...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, eased 0.9% higher at 125.2 points. Elsewhere, the OTCQX Cannabis index fell 1% to 504.6 points. Buds today are TILT Holdings Inc (CSE:TILT) (OTCMKTS:TLLTF), Aphria Inc (TSE:APHA)...

12 hours, 13 minutes ago

2 min read